NDLI: Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

Content Provider	PubMed Central
Author	Saroj, Vadhan-raj Goldberg, Jenna D. Perales, Miguel-angel Berger, Dietmar P. Brink, Marcel Rm
Copyright Year	2013
Abstract	Mucositis is one of the most significant toxicities in cancer patients undergoing cytotoxic treatment. It can have a negative impact on both quality of life and health economics. Severe oral mucositis can contribute to hospitalization, need for narcotic analgesics, total parentral nutrition, suboptimal delivery of anti-neoplastic treatment, and morbidity and mortality. Palifermin, a recombinant derivative of human keratinocyte growth factor, is the first active agent approved by the FDA for the prevention of severe oral mucositis in patients undergoing haematopoietic stem cell transplantation (HSCT). Several studies have also shown significant reduction in the incidence, severity and/or duration of oral mucositis in other high-risk settings such as concurrent chemoradiotherapy (CT/RT) for patients with head and neck cancer, and use of mucotoxic chemotherapeutic agents such as doxorubicin in sarcoma and fluorouracil for the treatment of colorectal cancer. The reduction in mucositis has translated into amelioration of symptoms and improvement in daily functioning as measured by patient-reported outcome in multiple studies. The clinical response to palifermin appears to be related in part to epithelial proliferation and mucosal thickening. Palifermin also has other potential clinical applications including the acceleration of immune reconstitution and inhibition of graft-versus-host disease in patients undergoing HSCT, and mitigation of dysphagia in lung cancer patients treated with concurrent CT/RT. Palifermin is generally well tolerated with mild-to-moderate skin and oral adverse events. Future studies may expand the use of palifermin into other areas that would benefit from its cytoprotective and regenerative effects.
Related Links	http://dx.doi.org/10.1111/jcmm.12169
Ending Page	1384
Page Count	14
Starting Page	1371
File Format	PDF
ISSN	15821838
e-ISSN	15824934
Journal	Journal of Cellular and Molecular Medicine
Issue Number	11
Volume Number	17
Language	English
Publisher	John Wiley & Sons
Publisher Date	2013-11-01
Access Restriction	Open
Rights Holder	John Wiley & Sons
Subject Keyword	Molecular Medicine Cell Biology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cell Biology Molecular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis

Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis

Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

Recent developments in palifermin basic, pre-clinical and clinical research

Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case–control study

Oncology, oral medicine: Palifermin for oral mucositis after intensive therapy for hematologic cancers

Emerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease

Palifermin for management of treatment-induced oral mucositis in cancer patients

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

Similar Documents

Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis

Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis

Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

Recent developments in palifermin basic, pre-clinical and clinical research

Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case–control study

Oncology, oral medicine: Palifermin for oral mucositis after intensive therapy for hematologic cancers

Emerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease

Palifermin for management of treatment-induced oral mucositis in cancer patients

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications